13F Holdings
中文EN

PLYX Polaryx Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2075320 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-114.9%
ROA-101.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets11.6%
Debt / equity0.00x
Current ratio8.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$6.27M$2.81M
SG&A expense$1.55M$1.54M
Operating income-$7.82M-$4.35M
Pretax income-$8.98M-$30.36M
Net income-$8.98M-$30.36M
EPS (basic)-0.20-0.89
EPS (diluted)-0.20-0.89
Weighted avg. shares (diluted)45.42M34.20M
Balance sheet
Cash & equivalents$5.14M$4.62M
Current assets$5.17M$5.00M
Total assets$5.17M$5.00M
Current liabilities$605,000$289,000
Total liabilities$605,000$289,000
Shareholders' equity$4.57M$4.71M
Shares outstanding47.34M41.15M
Cash flow statement
Operating cash flow-$3.94M-$2.57M
Financing cash flow$4.47M$7.19M
Stock-based compensation$4.72M$2.40M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.